Monte Rosa Therapeutics, Inc. (GLUE) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Monte Rosa Therapeutics, Inc. (GLUE) closed at USD 9.84 on 2026-10-14, a change of -20.8 % over the past year, with a market capitalization of USD 863.37M.

Monte Rosa Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Monte Rosa Therapeutics, Inc. key figures

Previous close

USD 9.84 (2026-10-14)

1-year change

-20.8 %

Market cap

USD 863.37M

Enterprise value

USD 280.25M

P/E ratio (trailing)

-5.92

P/E ratio (forward)

-5.20

EPS (trailing)

-1.71

EPS (forward)

-1.95

PEG ratio

n/a

Price to book

1.77

Revenue growth

-61.3 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

17.52

Employees

173

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Monte Rosa Therapeutics, Inc. and compare it with other stocks.